J Clin Invest. 2016;126(9):3383-3388. https://doi.org/10.1172/JCI84894. Autonomous thyroid adenomas (ATAs) are a frequent cause of hyperthyroidism. Mutations in the genes encoding the TSH receptor (TSHR) or the Gs protein a subunit (GNAS) are found in approximately 70% of ATAs. The involvement of other genes and the pathogenesis of the remaining cases are presently unknown. Here, we performed whole-exome sequencing in 19 ATAs that were paired with normal DNA samples and identified a recurrent hot-spot mutation (c.1712A>G; p.Gln571Arg) in the enhancer of zeste homolog 1 (EZH1) gene, which codes for a catalytic subunit of the polycomb complex. Targeted screening in an independent cohort confirmed that this mutation occurs with high frequency (27%) in ATAs. EZH1 mutations were strongly associated with known (TSHR, GNAS) or presumed (adenylate cyclase 9 [ADCY9]) alterations in cAMP pathway genes. Furthermore, functional studies revealed that the p.Gln571Arg EZH1 mutation caused increased histone H3 trimethylation and increased proliferation of thyroid cells. In summary, this study revealed that a hot-spot mutation in EZH1 is the second most frequent genetic alteration in ATAs. The association between EZH1 and TSHR mutations suggests a 2-hit model for the pathogenesis of these tumors, whereby constitutive activation of the cAMP pathway and EZH1 mutations cooperate to induce the hyperproliferation of thyroid cells.
Introduction
Autonomous thyroid adenomas (ATAs) are a major cause of hyperthyroidism, especially in iodine-deficient areas (1, 2) . The thyroid-stimulating hormone (TSH) plays a major role in controlling the function and growth of thyroid cells. Binding of TSH to its receptor stimulates cAMP production and the subsequent activation of protein kinase A (PKA), leading to thyroid hormone production and cell proliferation. Consistently, activating mutations in the TSH receptor (TSHR) have been found in up to 70% of ATAs (1, 3, 4) . In addition, a minority of these tumors carry an activating mutation in the Gs protein α subunit (GNAS) gene (1, 3, 4) . While it is well established that constitutive activation of the cAMP/PKA pathway plays an important role in uncontrolled thyroid hormone secretion, it is presently unclear whether this is sufficient to induce the formation and/or expansion of thyroid adenomas. Moreover, the pathogenesis of a relevant fraction (approximately 30%) of ATAs that do not harbor TSHR or GNAS mutations is presently unknown. Only a minor fraction of the TSHR and GNAS mutation-negative tumors identified in early studies may represent false negatives (5, 6) .
Whole-exome sequencing of matched tumor and normal samples is a powerful method for identifying somatic mutations implicated in tumor development. This approach is particularly effective in the case of well-differentiated tumors, which harbor few mutations. Using this approach, the molecular pathogenesis of several endocrine diseases associated with hormone hypersecretion was recently clarified (7) (8) (9) . Above all, this led to the identification of mutations in the catalytic α subunit of PKA (PRKACA) as being responsible for Cushing's syndrome due to cortisolsecreting adrenocortical adenomas (8) .
In this study, we performed next-generation whole-exome sequencing in a large series of ATAs to investigate the genetic alterations underlying these tumors. We found that a relevant fraction of ATAs carry a recurrent hot-spot mutation in a key gene involved in the regulation of cell differentiation and proliferation.
Results and Discussion
By performing whole-exome sequencing in 19 ATAs and paired normal samples, we identified a total of 94 candidate somatic mutations (81 missense, 5 nonsense, 3 frameshift, 3 direct splic-Autonomous thyroid adenomas (ATAs) are a frequent cause of hyperthyroidism. Mutations in the genes encoding the TSH receptor (TSHR) or the Gs protein α subunit (GNAS) are found in approximately 70% of ATAs. The involvement of other genes and the pathogenesis of the remaining cases are presently unknown. Here, we performed whole-exome sequencing in 19 ATAs that were paired with normal DNA samples and identified a recurrent hot-spot mutation (c.1712A>G; p.Gln571Arg) in the enhancer of zeste homolog 1 (EZH1) gene, which codes for a catalytic subunit of the polycomb complex. Targeted screening in an independent cohort confirmed that this mutation occurs with high frequency (27%) in ATAs. EZH1 mutations were strongly associated with known (TSHR, GNAS) or presumed (adenylate cyclase 9 [ADCY9]) alterations in cAMP pathway genes. Furthermore, functional studies revealed that the p.Gln571Arg EZH1 mutation caused increased histone H3 trimethylation and increased proliferation of thyroid cells. In summary, this study revealed that a hot-spot mutation in EZH1 is the second most frequent genetic alteration in ATAs. The association between EZH1 and TSHR mutations suggests a 2-hit model for the pathogenesis of these tumors, whereby constitutive activation of the cAMP pathway and EZH1 mutations cooperate to induce the hyperproliferation of thyroid cells.
Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas Davide Calebiro, 1,2 Elisa S. Grassi, 3 Markus Eszlinger, 4,5 Cristina L. Ronchi, 6 Amod Godbole, 1,2 Kerstin Bathon, 1, 2 Fabiana Guizzardi, 3 Tiziana de Filippis, 3 Knut Krohn, 7 Holger Jaeschke, 5 Thomas Schwarzmayr, 8, 9 Rifat Bircan, 10 Hulya Iliksu Gozu, 11 Seda Sancak, 12 Marek Niedziela, 13 Tim M. Strom, 8, 9 Martin Fassnacht, 6 . This recurrent pattern of a heterozygous somatic mutation was highly suggestive of a gain-of-function mode of action.
No correlation was found between the mutational status and the available clinical data (Supplemental Table 3 ), including age at surgery, tumor size, and thyroid function tests (TSH, FT4, and FT3 levels as well as AbTg and AbTPO positivity). On the basis of these initial results, we screened a large series of thyroid nodule samples (n = 304) for the presence of the hot-spot EZH1 c.1712A>G mutation. These samples comprised 94 ATAs diagnosed in adults, 29 ATAs diagnosed in children and adolescents, 59 normal surrounding tissue samples (NSTs) of ATAs, 82 scintigraphically cold (i.e., nonfunctioning) thyroid nodules (CTNs), 16 follicular thyroid carcinomas (FTCs), and 24 papillary thyroid carcinomas (PTCs). Interestingly, the hot-spot EZH1 mutation was found in 25 of 94 (27%) of the adult ATAs but not in any of the other samples ( Figure 1B) . A summary of the clinical parameters and mutational status of the adult ATA patients is presented in Supplemental Table 4 . The absence of the hot-spot EZH1 mutation in FTCs and PTCs suggests that ATAs carrying this mutation are not a precursor to carcinoma. Further-ing, and 2 indel; median: 4 somatic mutations in exonic regions per ATA sample; range: 0-12; Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/ JCI84894DS1). On the basis of a prediction of functional effects with the PolyPhen-2 software, 28 mutations were classified as probably damaging, 12 as possibly damaging, and 37 as benign. A detailed list of the observed somatic mutations is provided in Supplemental Table 1 . These mutations affected a total of 84 genes, 78 of which were associated with a Gene Ontology (GO) term. A canonical pathway analysis (Supplemental Table 2 ) recognized the PDGF receptor pathway (n = 5 genes) and the GPCR pathway (n = 9 genes) as most significantly represented. The latter included 5 GPCRs (TSHR, galanin receptor 2 [GALR2], olfactory receptor family 2 subfamily G member 2 [OR2G2], olfactory receptor family 5 subfamily M member 3 [OR5M3], and taste 1 receptor member 2 [TAS1R2]; see also Appendix 1 and Supplemental Figure 2 ), the Gs protein α subunit (GNAS), adenylyl cyclase 9 (ADCY9), and the ribosomal protein S6 kinase (RPS6KA3). Mutations affecting 3 genes (enhancer of zeste homolog 1 [EZH1], thyroglobulin [TG], and TSHR) were found in at least 2 samples and were therefore considered to be recurrent. In particular, a hotspot substitution (c.1712A>G; p.Gln571Arg) in EZH1 was found in 4 tumors (21% of cases) ( Figure 1A) . The c.1712A>G substitution divided into 5 groups ( Figure 1C ). Similar results were obtained in the validation cohort when considering TSHR and EZH1 mutations ( Figure 1D ). In the validation cohort, approximately onethird (21 of 62, 34%) of the TSHR mutation-positive ATAs harbored an EZH1 c.1712A>G mutation. Similar allelic percentages in a subgroup of 8 ATAs suggested a possible clonal origin of the cells with both mutations (Supplemental Figure 3) . EZH1 codes for a catalytic subunit of the polycomb repressive complex 2 (PRC2), which is implicated in the maintenance of embryonic stem cell pluripotency and plasticity. EZH1, a SET domain-containing histone methyltransferase, exerts its effects by catalyzing the mono-, di-and trimethylation of histone H3 at Lys27, leading to transcriptional repression of the associated genes (11, 12) . PRC2 has been linked to the aggressiveness of various cancers (13, 14) , and selective EZH1/2 inhibitors have been proposed as a novel anticancer strategy (15) . more, the lack of EZH1 mutations in pediatric ATAs suggests that these adenomas might represent a separate entity or that EZH1 mutations might be acquired later in the natural history of these tumors. No EZH1 mutations were found in either the thyroid tissue or peripheral leukocytes of members of a family with the rare condition of nonautoimmune hyperfunctioning thyroid hyperplasia associated with germline, activating TSHR mutations (10), nor were these mutations found in a 2-year-old female with a sporadic case. Remarkably, in the ATA group investigated by exome sequencing, EZH1 mutations were found only in samples carrying known mutations in other genes of the cAMP pathway, i.e., TSHR (n = 2) and GNAS (n = 1), or a potentially damaging mutation in ADCY9 (n = 1). Considering the known mutations affecting GPCR signaling (TSHR, GNAS), the hot-spot EZH1 mutation, and variations in other genes of the GPCR-signaling pathway, the ATAs analyzed by exome sequencing could be H3 methylation in a subset of ATA samples with or without the EZH1 mutation. All analyzed ATAs with EZH1 mutation had higher trimethylation levels and a tendency toward lower dimethylation levels compared with those detected in both the corresponding NST samples and the EZH1 mutation-negative ATAs ( Figure  3C ). The increase in histone H3 trimethylation is similar to that found with EZH2 mutations in follicular and diffuse large B cell lymphomas (16) . However, the mechanism is probably different. The EZH2 mutations in B cell lymphomas affect residues (Y641 and Y677) that are directly involved in substrate binding (14) , thus altering the substrate specificity in favor of dimethylated histone H3 and ultimately leading to increased Lys27 trimethylation (17) . The EZH1 mutation found in our study (Gln571Arg) affects a solvent-exposed residue in a region that is highly conserved between EZH1 and EZH2. Given the information available for EZH2, this residue is probably not involved in substrate binding but might play a role in the interaction with the suppressor of zeste 12 homolog (SUZ12) subunit of PRC2 and the cofactor adipocyte enhancer-binding protein 2 (AEBP2), which is required for optimal enzymatic activity (18, 19) (Figure 2, B and C) . Thus, we investigated the interaction between the Gln571Arg mutant and PRC2 components (SUZ12, AEBP2, and embryonic ectoderm
The amino acid change (Gln571Arg) identified in ATAs in this study involves a highly conserved amino acid in the catalytic (SET) domain of EZH1 (Figure 2A ). The position of this residue in a PRC2 model based on the partially solved x-ray structure of the closely related homolog EZH2 (14) is shown in Figure 2 , B and C. This amino acid immediately precedes a cysteine residue, which is directly involved in the coordination of a zinc atom in the second zinc-binding domain (14) .
Given these findings, we investigated whether the Gln571Arg mutation was affecting EZH1 activity in intact cells. For this purpose, we transfected HEK293 cells with either WT or mutant EZH1 and evaluated histone H3 methylation using Abs specific to mono-, di-, or trimethylated Lys27. Expression levels of both WT and mutant EZH1 protein were similar, indicating that the Gln571Arg mutation was not affecting protein stability ( Figure  3A) . Remarkably, expression of the Gln571Arg mutant caused a strong increase in histone H3 trimethylation, accompanied by a concomitant decrease in dimethylation ( Figure 3A) . Moreover, an increase in histone H3 methylation was observed upon expression of the Gln571Arg mutant in 2 rat thyroid cell models: transiently transfected PCCL3 and stably transfected Fischer rat thyroid (FRT) cells ( Figure 3B ). In addition, we analyzed histone Figure 4 ). No differences were detected between WT and mutant EZH1 proteins, suggesting that the Gln571Arg mutation does not grossly alter these interactions. Detailed structural studies will be required to further dissect the mechanisms underlying the increased activity caused by the Gln571Arg mutation.
Finally, we evaluated whether the EZH1 Gln571Arg substitution was affecting the proliferation of thyroid cells. For this purpose, we generated FRT cells stably expressing WT EZH1 or the Gln571Arg mutant. Stable expression of the Gln571Arg mutant was associated with increased cell proliferation ( Figure 3D ). This effect was accompanied by a strong increase in the levels of cyclin D1 and histone H3 phosphorylation at Ser10, two cell proliferation markers ( Figure 3E ). In addition, we compared the effects of transient EZH1 transfection in 2 FRT clones stably expressing the WT TSHR or an activating TSHR mutant (V597F) (20) . In contrast to transfection of WT EZH1, which had only a moderate proliferative effect, transfection of the mutant EZH1 caused a strong increase of cell proliferation in both cell lines (Supplemental Figure 5 ). These data suggest that the Gln571Arg mutant has a relevant impact on the proliferation of thyroid cells and can increase cell proliferation also in the presence of an activating TSHR mutant.
In conclusion, this study identifies EZH1 mutations as the second most frequent genetic alteration in ATAs. Gain-of-function TSHR mutations may well be sufficient to support thyroid autonomy and hyperplasia, as thyroid-stimulating Abs (TSAbs) do in Graves' disease. However, we propose that their association with EZH1 mutations such as those found in a relevant subset of ATAs in this study -or with other still-unknown events giving advantage over normal thyroid cells -might further promote adenoma growth according to a "2-hit" model. Testing for the EZH1 Gln571Arg hot-spot mutation might help in the molecular diagnosis and classification of thyroid nodules. Moreover, interfering with EZH1 function might be of potential therapeutic benefit in thyroid disorders associated with increased cell proliferation. Additional mutations and/or pathogenic mechanisms remain to be identified for cases that are both TSHR and EZH1 mutation negative.
